N. Concin, X. Matias-Guiu, I. Vergote, D. Cibula, M.R. Mirza, S. Marnitz, J. Ledermann, T. Bosse, C. Chargari, A. Fagotti et al., ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 31, 12–39 (2021). https://doi.org/10.1136/ijgc-2020-002230

Article  PubMed  Google Scholar 

M.A. Sheikh, A.D. Althouse, K.E. Freese, S. Soisson, R.P. Edwards, S. Welburn, P. Sukumvanich, J. Comerci, J. Kelley, R.E. Laporte et al., USA Endometrial Cancer Projections to 2030: should we be concerned? Future Oncol. 10, 2561–2568 (2014). https://doi.org/10.2217/fon.14.192

Article  CAS  PubMed  Google Scholar 

M. Koskas, F. Amant, M.R. Mirza, C.L. Creutzberg, Cancer of the Corpus Uteri: 2021 update. Int. J. Gynecol. Obstet. 155, 45–60 (2021). https://doi.org/10.1002/ijgo.13866

Article  Google Scholar 

J.V. Bokhman, Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15, 10–17 (1983). https://doi.org/10.1016/0090-8258(83)90111-7

Article  CAS  PubMed  Google Scholar 

M. Remmerie, V. Janssens, Targeted therapies in type II endometrial cancers: too little, but not too late. Int. J. Mol. Sci. 19, 2380 (2018). https://doi.org/10.3390/ijms19082380

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.B. Gilks, E. Oliva, R.A. Soslow, Poor Interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 37, 874–881 (2013). https://doi.org/10.1097/PAS.0b013e31827f576a

Article  PubMed  Google Scholar 

G. Getz, S.B. Gabriel, K. Cibulskis, E. Lander, A. Sivachenko, C. Sougnez, M. Lawrence, C. Kandoth, D. Dooling, R. Fulton et al., Integrated genomic characterization of endometrial carcinoma. Nature. 497, 67–73 (2013). https://doi.org/10.1038/nature12113

Article  CAS  Google Scholar 

M. Alexa, A. Hasenburg, M.J. Battista, The Tcga molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers (Basel). 13 (2021). https://doi.org/10.3390/cancers13061478

D. Arciuolo, A. Travaglino, A. Raffone, D. Raimondo, A. Santoro, D. Russo, S. Varricchio, P. Casadio, F. Inzani, R. Seracchioli et al., TCGA molecular prognostic groups of endometrial carcinoma: current knowledge and future perspectives. Int. J. Mol. Sci. 23 (2022). https://doi.org/10.3390/ijms231911684

L. Zong, S. Mo, Z. Sun, Z. Lu, J. Chen, S. Yu, Y. Xiang, Incorporating molecular classification when stratifying the survival risk of patients with high-grade endometrial carcinomas. J. Clin. Med. 12 (2023). https://doi.org/10.3390/jcm12020530

A. Leon-Castillo, De S.M. Boer, M.E. Powell, L.R. Mileshkin, H.J. Mackay, A. Leary, H.W. Nijman, N. Singh, P.M. Pollock, P. Bessette et al., Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J. Clin. Oncol. 38, 3388–3397 (2020). https://doi.org/10.1200/JCO.20.00549

Article  CAS  PubMed  PubMed Central  Google Scholar 

J.S. Berek, X. Matias-Guiu, C. Creutzberg, C. Fotopoulou, D. Gaffney, S. Kehoe, K. Lindemann, D. Mutch, N. Concin, J.S. Berek et al., FIGO Staging of endometrial cancer: 2023. Int. J. Gynaecol. Obstet. 162, 383–394 (2023). https://doi.org/10.1002/ijgo.14923

Article  Google Scholar 

M. Remmerie, V. Janssens, PP2A: a promising biomarker and therapeutic target in endometrial cancer. Front. Oncol. 9, 462 (2019). https://doi.org/10.3389/fonc.2019.00462

Article  PubMed  PubMed Central  Google Scholar 

L. Tortorella, C.L. Langstraat, A.L. Weaver, M.E. McGree, J.N. Bakkum-Gamez, S.C. Dowdy, W.A. Cliby, G.L. Keeney, M.E. Sherman, S.J. Weroha et al., Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol. Oncol. 149, 291–296 (2018). https://doi.org/10.1016/j.ygyno.2018.02.022

Article  CAS  PubMed  Google Scholar 

C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, T.A. Longacre, M.A. Powell, M.R. Hendrickson, D.S. Kapp, J.K. Chan, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to Grade 3 endometrioid corpus cancers. Br. J. Cancer. 94, 642–646 (2006). https://doi.org/10.1038/sj.bjc.6603012

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Kreutzfeldt, B. Rozeboom, N. Dey, P. De, The trastuzumab era: current and upcoming targeted HER2 + breast cancer therapies. Am. J. Cancer Res. 10, 1045–1067 (2020)

PubMed  PubMed Central  Google Scholar 

A.N. Fader, D.M. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, S. Chambers, A.A. Secord, L. Havrilesky, D.M. O’Malley et al., Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (Stage III–IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis. Clin. Cancer Res. 26, 3928–3935 (2020). https://doi.org/10.1158/1078-0432.CCR-20-0953

Article  PubMed  PubMed Central  Google Scholar 

C. Gray, C. Argáez, Trastuzumab Combination and Monotherapy for HER2 Advanced or Recurrent Uterine or Endometrial Cancer: A Review of Clinical Effectiveness and Cost-Effectiveness (Ottawa (ON), 2020)

V. Janssens, J. Goris, Van C. Hoof, PP2A: the expected tumor suppressor. Curr. Opin. Genet. Dev. 15, 34–41 (2005). https://doi.org/10.1016/j.gde.2004.12.004

Article  CAS  PubMed  Google Scholar 

D. Haesen, L.A. Asbagh, R. Derua, A. Hubert, S. Schrauwen, Y. Hoorne, F. Amant, E. Waelkens, A. Sablina, V. Janssens, Recurrent PPP2R1A mutations in Uterine Cancer Act through a dominant-negative mechanism to promote malignant cell growth. Cancer Res. 76, 5719–5731 (2016). https://doi.org/10.1158/0008-5472.CAN-15-3342

Article  CAS  PubMed  Google Scholar 

L. Lenaerts, S. Reynhout, I. Verbinnen, F. Laumonnier, A. Toutain, F. Bonnet-Brilhault, Y. Hoorne, S. Joss, A.K. Chassevent, C. Smith-Hicks et al., The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. Genet. Sci. 23, 352–362 (2021). https://doi.org/10.1038/s41436-020-00981-2

Article  CAS  Google Scholar 

C.M. O’Connor, D. Leonard, D. Wiredja, R.A. Avelar, Z. Wang, D. Schlatzer, B. Bryson, E. Tokala, S.E. Taylor, A. Upadhyay et al., Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors. Oncogene 39, 703–717 (2020). https://doi.org/10.1038/s41388-019-1012-2

Article  CAS  PubMed  Google Scholar 

S.E. Taylor, C.M. O’Connor, Z. Wang, G. Shen, H. Song, D. Leonard, J. Sangodkar, C. LaVasseur, S. Avril, S. Waggoner et al., The highly recurrent PP2A Aa-Subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis. Cancer Res. 79, 4242–4257 (2019). https://doi.org/10.1158/0008-5472.CAN-19-0218

Article  CAS  PubMed  PubMed Central  Google Scholar 

C.M. O’Connor, S.E. Taylor, K.M. Miller, L. Hurst, T.J. Haanen, T.K. Suhan, K.P. Zawacki, F.K. Noto, J. Trako, A. Mohan et al., Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Res. 82, 721–733 (2022). https://doi.org/10.1158/0008-5472.CAN-21-1987

Article  PubMed  PubMed Central  Google Scholar 

S. Zhao, M. Choi, J.D. Overton, S. Bellone, D.M. Roque, E. Cocco, F. Guzzo, D.P. English, J. Varughese, S. Gasparrini et al., Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc. Natl. Acad. Sci. U S A 110, 2916–2921 (2013). https://doi.org/10.1073/pnas.1222577110

Article  PubMed  PubMed Central  Google Scholar 

C. Cokelaere, R. Dok, E.E. Cortesi, P. Zhao, A. Sablina, S. Nuyts, R. Derua, V. Janssens, TIPRL1 and its ATM-dependent phosphorylation promote radiotherapy resistance in head and neck cancer. Cell. Oncol. (2023). https://doi.org/10.1007/s13402-023-00895-6

Article  Google Scholar 

J.C. Silva, M.V. Gorenstein, G.Z. Li, J.P.C. Vissers, S.J. Geromanos, Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol. Cell. Proteomics. 5, 144–156 (2006). https://doi.org/10.1074/mcp.M500230-MCP200

Article  CAS  PubMed  Google Scholar 

T. Ayakannu, A.H. Taylor, J.C. Konje, Selection of endogenous control reference genes for studies on type 1 or type 2 endometrial cancer. Sci. Rep. 10, 8468 (2020). https://doi.org/10.1038/s41598-020-64663-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Zhenchuk, K. Lotfi, G. Juliusson, F. Albertioni, Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem. Pharmacol. 78, 1351–1359 (2009). https://doi.org/10.1016/j.bcp.2009.06.094

Article  CAS  PubMed  Google Scholar 

W.P. Roos, A.D. Thomas, B. Kaina, DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 16, 20–33 (2016). https://doi.org/10.1038/nrc.2015.2

Article  CAS  PubMed